zurück

Selinexor (multiple myeloma, ≥ 1 prior therapy, in combination with bortezomib and dexamethasone)

 

Subject:

  • Active Substance: Selinexor
  • Name: Nexpovio®
  • Therapeutic area: Multiple myeloma
  • Pharmaceutical company: Stemline Therapeutics B.V.

 

Time table:

  • Start: 01.10.2022
  • Final decision by G-BA: 16.03.2023

 

Final decision:

  • No additional benefit proved